ArticlePrzeglad gastroenterologiczny2017
The efficacy and safety of the biosimilar product (Inflectra
Article in Przeglad gastroenterologiczny, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Infliximab versus ciclosporin in steroid resistant acute severe ulcerative colitis: a model-based cost-utility analysis of data from CONSTRUCT pragmatic trial.BMC health services research · 2023Trial
- Multiplexed Immunophenotyping for Innate Activation Assessment Detects Single-Cell Responses to Immunomodulatory Nucleic Acid Impurities in Therapeutics.The AAPS journal · 2026Article
- Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting.Rheumatology and therapy · 2024Article
- Observational
- Biological Therapies for the Management of Enteric Disease: Considerations for the Clinician.Biologics : targets & therapy · 2022Review
- Real-world data on the infliximab biosimilar CT-P13 (RemsimaWorld journal of clinical cases · 2021Article
- Biosimilar infliximab versus originator in Crohn's disease anti-TNF-α naïve and non-naïve patients.Przeglad gastroenterologiczny · 2021Article
- Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis.International journal of colorectal disease · 2020Review
- Knowledge and Viewpoints on Biosimilar Monoclonal Antibodies among Asian Physicians: Comparison with European Physicians.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2019Article
- Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules.Journal of clinical medicine · 2019Review
- Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?Biologics : targets & therapy · 2019Article
- Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective.Therapeutic advances in gastroenterology · 2019Review
- Contemporary Medical Management of Acute Severe Ulcerative Colitis.Inflammatory bowel diseases · 2019Review
- Effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting in patients with Crohn's disease or ulcerative colitis.Journal of drug assessment · 2019Article
- Biosimilar biological drugs in the treatment of inflammatory bowel diseases.Przeglad gastroenterologiczny · 2019Review
- Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe biosimilar product Inflectra
aimTo assess the efficacy and safety of the biosimilar product Inflectra MATERIAL AND
methodsIn a single-centre retrospective study, a cohort of 83 adult patients with severe UC treated at the Department of Gastroenterology with Inflammatory Bowel Diseases Subdivision of the Central Clinical Hospital of MSWiA, Warsaw was investigated. All patients received three induction doses of Remicade
resultsThe studied groups were similar with respect to age and sex distribution, duration of the disease, extent of the disease (left-sided type, pancolitis), additional pharmacotherapy, and smoking. Clinical response following three induction doses was noted in 81% of patients receiving Remicade
conclusionsIn the study, it was established that the biosimilar drug (Inflectra
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.